CN112156143B - Compound nutrient composition with antioxidant function - Google Patents
Compound nutrient composition with antioxidant function Download PDFInfo
- Publication number
- CN112156143B CN112156143B CN202011252060.4A CN202011252060A CN112156143B CN 112156143 B CN112156143 B CN 112156143B CN 202011252060 A CN202011252060 A CN 202011252060A CN 112156143 B CN112156143 B CN 112156143B
- Authority
- CN
- China
- Prior art keywords
- parts
- selenium
- nutrient composition
- grape seed
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 46
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 34
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 24
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims description 21
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 66
- 239000011669 selenium Substances 0.000 claims abstract description 66
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 55
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 54
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 54
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 54
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- 239000008187 granular material Substances 0.000 claims description 43
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 23
- 239000002775 capsule Substances 0.000 claims description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 240000002547 Rosa roxburghii Species 0.000 claims description 3
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 56
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 230000009758 senescence Effects 0.000 abstract description 2
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 68
- 238000002156 mixing Methods 0.000 description 50
- 241001122767 Theaceae Species 0.000 description 47
- 238000007873 sieving Methods 0.000 description 35
- 150000003254 radicals Chemical class 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 102000019197 Superoxide Dismutase Human genes 0.000 description 28
- 108010012715 Superoxide dismutase Proteins 0.000 description 28
- 235000006708 antioxidants Nutrition 0.000 description 26
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 24
- 229940118019 malondialdehyde Drugs 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 19
- 230000006870 function Effects 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000011049 filling Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 239000011812 mixed powder Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000005686 eating Nutrition 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 4
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 4
- 229920002414 procyanidin Polymers 0.000 description 4
- 235000017784 Mespilus germanica Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000182216 Mimusops elengi Species 0.000 description 3
- 235000000560 Mimusops elengi Nutrition 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 235000007837 Vangueria infausta Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940087559 grape seed Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 235000021195 test diet Nutrition 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000000852 hydrogen donor Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 101100489891 Mus musculus Abcg2 gene Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a compound nutrient preparation with an antioxidant function, which comprises the following raw materials: grape seed extract, tea polyphenols and selenium. The three components are compatible, so that the antioxidant effect is better exerted, and the effects of scavenging free radicals, delaying senescence and protecting organisms are achieved. The preparation process is simple, the cost is low, the stability is good, the preparation conforms to the pharmacopeia standard, the product is convenient to carry and take, and no side effect or drug dependence is generated on a human body.
Description
Technical Field
The invention relates to the field of medicine and health care, and relates to a compound nutrient preparation with an antioxidant function and a preparation method thereof.
Background
Free radicals are chemical substances, also called active oxygen, which are very active and have strong oxidation effect and are generated by human cells in the metabolic process. Free radicals are ubiquitous in the human body, and the attack routes are also multifaceted. When the free radicals in the human body exceed a certain amount and lose control, the free radicals run and flee, attack cell membranes, oxidize serum antitrotease, even grab electrons of DNA, damage healthy cells of the human body, and induce diseases such as cardiovascular diseases, diabetes, age-related macular degeneration, cancers and the like. In addition, the damage of the different cells by free radicals can lead to the degeneration of seemingly unrelated diseases, so that the cells cannot absorb nutrients from the outside, cannot discharge intracellular metabolites and lose the defense against cells and viruses. Reducing the immunity of human body, so that some people are called as the source of 'ten thousands of diseases' by free radicals.
Aging of the human body is also inseparable from free radicals. United kingdom pioneered in 1956 the association of free radicals with body ageing and disease, followed by a first study report in 1957 demonstrating that mice fed with feed containing 0.5% to 1% free radical scavenger have an extended lifespan. The central content of the theory of free radical aging is that aging results from the random and destructive action of free radicals generated in the normal metabolic processes of the body. The causes of aging of the body caused by free radicals in the human body can be summarized into three aspects: cross-linking polymerization of living macromolecules and lipofuscin accumulation; destruction and reduction of organ tissue cells; and simultaneously, the immune function is reduced, thereby causing diseases and aging of the human body.
The formation of free radicals in the human body is ubiquitous, and the generation of free radicals is promoted by sunlight, radiation, ozone, and the like. In daily life, free radicals may come from outside the body or from inside the body. Free radicals can be induced by in vitro sources such as smoking, sun exposure, food preservatives, pesticides, chemical carcinogens (e.g., certain drugs, plastics, etc.), pesticides, radiation, etc. Scientific research shows that smoking is the fastest and most free radical generating mode at present, more than one hundred thousand free radicals can be generated after smoking each cigarette, systemic cancer can be caused, and the growth of cancer cells, particularly lung cancer, can be accelerated. It also causes a number of chronic diseases, such as cardiovascular disease and diabetes. Excessive mental stress can also induce excessive formation of free radicals in vivo when the mood fluctuates sharply.
In recent years, research on free radicals and free radical scavengers is active at home and abroad, and many research reports on free radicals and scavengers thereof are reported in various food sciences, life sciences and medical books.
In the prior art, grape seed extract, tea polyphenol and selenium-enriched yeast as functional components can be added into food, feed and other products at the same time, for example, CN104982723A discloses a feed premix; CN108142763A and CN108433107A disclose drinking water added with functional components; CN109156603A discloses a compound premix feed. Although these prior arts contain the above antioxidant component, since the use of selenium has an upper limit (safety problem) in human body, the addition amounts of grape seed extract and tea polyphenol are limited in the technical solutions of CN104982723A, CN108142763A and CN108433107A when the content of selenium is limited. In addition, the above prior arts all study the dosage ratio of the three components. The application further researches the dosage and the proportion of the three components to find that the three components can achieve better antioxidant effect in a specific proportion.
Disclosure of Invention
The invention screens natural antioxidant raw materials, takes grape seed extract, tea polyphenol and selenium-enriched yeast as raw materials to be compounded and combined, and combines the modern preparation process to form the compound nutrient preparation with the functions of removing free radicals and resisting oxidation.
The grape seed extract is extracted from grape seed, and its main component procyanidin content is up to above 95%, and procyanidin is polyphenol compound, and it has several phenolic hydroxyl groups, and can be combined with excess free radical in vivo, the main component procyanidin of grape seed extract has the combined effect of polyphenol, and its antioxidant activity has multifaceted and multi-targeted action, and it is found in research make internal disorder or usurp for evaluating antioxidant activity of grape seed procyanidin by using key enzyme activities (superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), etc.), and it can utilize hydrogen interaction, hydrophobic interaction and electrostatic interaction to block enzyme site to exert its antioxidant activity, and it can make in vivo after-translation modification of enzyme to raise antioxidant enzyme activity, and it also can participate in fatty acid metabolism of organism, Proteins are phosphorylated and can act as powerful metal chelators.
Tea leaves are considered as a natural health food with prevention and treatment effects on various common diseases of human bodies, and the tea leaves play a key role in tea polyphenol, wherein the tea polyphenol has an antioxidation effect because phenolic hydroxyl groups on a B ring and a C ring of catechin have the activity of hydrogen donors, and ortho-quinones and diphenol quinones are generated in the oxidation process. It can effectively eliminate oxygen free radicals and lipid free radicals, prevent lipid peroxidation, and has the functions of inhibiting tumor occurrence, delaying aging, etc.
Selenium is an essential trace element for organisms, participates in the decomposition reaction of catalytic peroxide in the organisms, and is an essential component of GSH-Px. GSH-Px is an important antioxidant enzyme forming a multi-level enzyme defense system for eliminating superoxide anion free radicals, and plays a very important role in preventing free radical mediated oxidative damage in vivo. Most biological effects of selenium are mediated by selenoprotein, selenium-enriched yeast is added in a yeast culture period, the selenium can be absorbed and utilized in the yeast growth process, the selenium can be organically combined with protein and polysaccharide in the yeast, inorganic selenium is converted into biological organic selenium, the original toxic and side effects of the inorganic selenium are eliminated, and the selenium can be absorbed and utilized by an organism more effectively and safely.
Although the three antioxidant substances of the grape seed extract, the tea polyphenol and the selenium exert the antioxidant activity thereof by different action mechanisms, the three antioxidant substances also have synergistic antioxidant effect. The combined test shows that the antioxidant enzyme activity of the grape seed extract is improved by modifying enzyme sites, and experiments prove that the grape seed extract can effectively eliminate a plurality of active oxygen generated by O.2,. OH, H2O2, ONOO-and whole blood neutrophil 'respiratory burst' to inhibit the system from emitting light and effectively inhibit lipid peroxidation; the tea polyphenol can directly remove free radicals by utilizing the activity of hydrogen donor, and can block the generation path of oxidase, inhibit the activity of oxidase and activate the antioxidant mechanism of organism; selenium is an essential component of GSH-Px and participates in the decomposition of peroxidized substances in the body. Through animal experiments, the following results are found: the combined use of the grape seed extract, the tea polyphenol and the selenium is more effective than the single use or the compatibility of two components, further proves the compound compatibility of the three components and has the synergistic antioxidation.
The rosa roxburghii tratt is a wild fruit produced in southwest region of China, mainly contains active ingredients such as polysaccharide, flavone, superoxide dismutase (SOD), Vitamin C (VC), triterpene and the like, and has pharmacological effects of resisting oxidation, resisting tumors, resisting atherosclerosis, preventing and treating diabetes, protecting radiation and the like. The fructus Lycii is a traditional Chinese medicinal material and food tonic, and has multiple active ingredients such as fructus Lycii polysaccharide, flavonoid, alkaloid, fructus Lycii pigment, amino acids, etc. A large number of researches show that the medlar has the physiological effects of resisting tumor, resisting oxidation, resisting aging, protecting liver, protecting eyes and the like. According to the invention, at least one of the roxburgh rose and the medlar is compounded and mixed with the grape seeds, the tea polyphenol and the selenium for use, so that the antioxidation effect of the composition can be further improved.
The invention aims to provide a compound nutrient preparation with an antioxidant function.
The compound nutrient composition with the antioxidant function comprises the following raw materials: grape seed extract, tea polyphenols, and selenium-rich yeast.
Furthermore, the compound nutrient composition comprises the following raw materials in parts by weight: 30-70 parts of grape seed extract, 20-50 parts of tea polyphenol and 2-10 parts of selenium-enriched yeast; preferably, the feed comprises the following raw materials in parts by weight: 35-60 parts of grape seed extract, 20-40 parts of tea polyphenol and 3-9 parts of selenium-enriched yeast, or 30-50 parts of grape seed extract, 25-45 parts of tea polyphenol and 2-8 parts of selenium-enriched yeast, or 40-65 parts of grape seed extract, 30-45 parts of tea polyphenol and 3-7 parts of selenium-enriched yeast; further preferably, the feed comprises the following raw materials in parts by weight: 38 parts of grape seed extract, 25 parts of tea polyphenol and 4 parts of selenium-enriched yeast.
The invention also provides a compound nutrient composition with an antioxidant function, which comprises the raw materials of grape seed extract, tea polyphenol and selenium-enriched yeast; and further comprises at least one of a Rosa roxburghii extract and a Lycium chinense extract.
The compound nutrient composition with the antioxidant function can be prepared into preparations; preferably prepared into a solid preparation; the solid preparation is capsule, tablet, powder, effervescent or granule.
The compound nutrient composition with the antioxidant function can be added with auxiliary material fillers, disintegrants, lubricants, effervescent disintegrants and the like when being prepared into preparations, wherein the fillers are selected from one or more of starch, compressible starch, microcrystalline cellulose, dextrin, sucrose, lactose, mannitol, inorganic salts and the like, the disintegrants are selected from one or more of dry starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose and the like, the effervescent disintegrants are selected from sodium bicarbonate, citric acid and the like, and the lubricants are selected from one or more of magnesium stearate, micro-powder silica gel, talcum powder, polyethylene glycol 400, polyethylene glycol 6000, hydrogenated vegetable oil and the like.
The compound nutrient composition has an antioxidant effect and can be used as a raw material of food, medicines, health-care products and cosmetics.
Compared with the prior art, the invention has the following advantages and beneficial effects:
the raw materials selected by the invention are green, safe and effective, the grape seed extract and the tea polyphenol are strong antioxidants extracted from natural plants, and the selenium-enriched yeast converts inorganic selenium into biological organic selenium, so that the selenium-enriched yeast has the advantages of good safety, favorable absorption and the like. The three components are compatible, so that the antioxidant effect is better exerted, and the effects of scavenging free radicals, delaying senescence and protecting organisms are achieved.
The result of a human body feeding test proves that the compound nutrient preparation with the antioxidant function has the antioxidant function, can reduce the MDA content of human serum, and improves the activities of antioxidant enzyme SOD and GSH-Px.
Detailed Description
The technical scheme of the invention is further explained by combining the specific embodiment as follows:
example 1
(1) Sieving: 75g of grape seed extract, 50g of tea polyphenol, 8.8g of selenium-enriched yeast and 212.2g of microcrystalline cellulose are respectively sieved by a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
Example 2
(1) Sieving: taking 65g of grape seed extract, 45g of tea polyphenol, 6g of selenium-enriched yeast, 50g of roxburgh rose extract and 180g of microcrystalline cellulose, and respectively sieving the grape seed extract, the tea polyphenol, the selenium-enriched yeast, the roxburgh rose extract and the microcrystalline cellulose with a sieve of 80 meshes for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, fructus Rosae Normalis extract and microcrystalline cellulose for 30min, and mixing.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
Example 3
Preparation of the granules of the invention
(1) Sieving: 60g of grape seed extract, 40g of tea polyphenol, 7g of selenium-enriched yeast, 42.5g of medlar extract and 196.5g of microcrystalline cellulose are respectively sieved by a sieve of 80 meshes for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, fructus Lycii extract, and microcrystalline cellulose for 30min, and mixing.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule. Animal experiment research on antioxidant function
Experiment of antioxidant effect:
first, animal experiment
1. Experimental methods
By comparing the antioxidant capacity of the grape seed extract + tea polyphenol, the grape seed extract + selenium, the tea polyphenol + selenium, the grape seed extract + VE + selenium and the grape seed extract + tea polyphenol + selenium, the antioxidant capacity of the antioxidant nutritional compound preparation provided by the invention is comprehensively evaluated by taking the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the content of Malondialdehyde (MDA) in the serum of a mouse as indexes.
2. Preparation of test samples
2.1 comparative sample 1 preparation
(1) Sieving: 80g of grape seed extract, 50g of tea polyphenol and 216g of microcrystalline cellulose are respectively sieved by a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
2.2 comparative sample 2 preparation
(1) Sieving: 90g of grape seed extract, 8.8g of selenium-enriched yeast and 247.2g of microcrystalline cellulose are respectively sieved by a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, selenium-rich yeast and microcrystalline cellulose for 30min, and mixing.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
2.3 comparative sample 3 preparation
(1) Sieving: taking 50g of tea polyphenol, 8.8g of selenium-enriched yeast and 287.2g of microcrystalline cellulose, and respectively sieving with a 80-mesh sieve for later use.
(2) Mixing the sieved tea polyphenols, selenium-rich yeast and microcrystalline cellulose for 30min, and mixing.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
2.4 comparative sample 4 preparation
(1) Sieving: 75g of grape seed extract, 5.5g of natural vitamin E, 8.8g of selenium-enriched yeast and 256.7g of microcrystalline cellulose are respectively sieved by a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, natural vitamin E, selenium-rich yeast and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
2.5 comparative sample 5 is the sample of example 1 above
3. After the test feeding, the results of the mouse antioxidant index are shown in the following table.
TABLE 3-1 Effect of mouse antioxidant index
As can be seen from Table 3-1, compared with the blank control, the serum MDA content in the serum of the aged mice of the comparative groups 1 and 2 is significantly reduced (P is less than 0.05), and the serum MDA content in the serum of the aged mice of the comparative groups 4 and 5 is significantly reduced (P is less than 0.001); compared with the comparison groups 1-4, the serum MDA content of the mice of the comparison group 5 is obviously reduced (P is less than 0.05). Compared with a blank control, the SOD activity in the serum of the mice with the age of 1 to 4 in the comparison group is obviously improved (P is less than 0.05), the SOD activity in the serum of the mice with the age of 5 in the comparison group is obviously improved (P is less than 0.001), and compared with the blood serum of the mice with the age of 5 in the comparison group is obviously improved (P is less than 0.001) in the comparison group 1 to 4. Compared with a blank control, the activity of the GSH-Px in the serum of the aged mice of the comparison groups 1, 2 and 4 is obviously improved (P is less than 0.05), and compared with the comparison groups 1 to 4, the activity of the GSH-Px in the serum of the aged mice of the comparison group 5 is obviously improved (P is less than 0.001).
4. Conclusion of the experiment
The MDA content reflects the severity of free radical attack on the organism, and after the organism is attacked by the free radical, lipid peroxidation is initiated, and MDA is further generated. SOD plays a crucial role in the balance of oxidation and antioxidation of the body, and the enzyme can remove O2 -Protection of cells from damage, the magnitude of SOD activity indirectly reflects the ability of the body to scavenge oxygen free radicals. The activity of GSH-Px reflects the reducing power of tissues and serum in a mouse, and the level indirectly reflects the elimination capability of the mouse to free radicals. 5 tested samples of grape seed extract plus tea polyphenol, grape seed extract plus selenium, tea polyphenol plus selenium, grape seed extract plus VE plus selenium, grape seed extract plus tea polyphenol plus selenium are orally administered to old mice. The test sample combined with other 4 groups of test samples, namely the grape seed extract, the tea polyphenol and the selenium can obviously reduce the MDA content in the serum of the mouse, and improve the activity of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD). The grape seed extract, the tea polyphenol and the selenium are compounded for use, the antioxidant effect is better than that of the combination of the grape seed extract, VE and the selenium, and the synergistic antioxidant effect is achieved.
Second, research on antioxidant function in human body
1. Study object
1.1 subject inclusion criteria
Selecting people who are 18-65 years old, have good physical health condition, no obvious brain, heart, liver, lung, kidney and blood diseases, no long-term medicine taking history and are matched with volunteers and testees.
1.2 criteria for excluding Subjects
1.2.1 pregnant or lactating women, allergic to health food.
1.2.2 patients with serious diseases such as heart, liver, kidney and hematopoietic system.
1.2.3 taking the article related to the tested function in a short time affects the judger of the result.
1.2.4 does not meet the inclusion standard, and if the test sample is not eaten according to the regulation, the efficacy or the data are not completely influenced or the safety is judged.
2. Experimental methods
Before intervention, the serum MDA content, SOD activity and GSH-Px activity of the study objects are detected, after hierarchical sequencing is carried out according to the levels of the serum MDA content, the SOD activity and the GSH-Px activity of the study objects, 300 study objects are randomly divided into test groups 1-4 and control groups according to a double-blind random control principle, and each group comprises 60 people. Test groups 1-4 subjects took 4 test samples (0.35 g/capsule) daily for 3 months, and the control group was a negative control. The normal life and diet of the five groups of subjects was unchanged during the trial. After the intervention is finished, health examination is carried out on five groups of study objects, fasting venous blood of the five groups of study objects is collected respectively, and after serum is separated, MDA content, SOD activity and GSH-Px activity of the serum of the study objects are measured by using the kit.
3. Preparation of test samples
Comparative example 1 (the ratio is in the range of 25-50 of grape seed extract (containing 40% polyphenol) described in CN104982723A, 50 of selenium yeast, and 25-50 of tea polyphenols)
(1) Sieving: taking 12g of grape seed extract, 12g of tea polyphenol, 12g of selenium-enriched yeast (reaching the upper limit of the dosage of adults), 174g of maltodextrin and 136g of microcrystalline cellulose, and respectively sieving the grape seed extract, the tea polyphenol and the selenium-enriched yeast with a sieve of 80 meshes for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, maltodextrin, and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
Comparative example 2 (the ratio is in the range of the ratio of 0.4-0.9 of grape seed extract, 2-4 of organic selenium, and 3-5 of tea polyphenols described in CN 108142763A)
(1) Sieving: taking 3.6g of grape seed extract, 30g of tea polyphenol, 12g of selenium-enriched yeast, 178g of maltodextrin and 122g of microcrystalline cellulose, and respectively sieving with a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, maltodextrin, and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
Comparative example 3 (the proportion is in the range of 10-16 of enzymolysis grape seed meal, 0.78 of yeast selenium and 0.6-1.0 of tea polyphenol recorded in CN 109156603A):
(1) sieving: taking 117.2g of grape seed extract, 10g of tea polyphenol, 7.8g of selenium-enriched yeast, 95g of maltodextrin and 116g of microcrystalline cellulose, and respectively sieving with a 80-mesh sieve for later use.
(2) Mixing the sieved grape seed extract, tea polyphenols, selenium-rich yeast, maltodextrin, and microcrystalline cellulose for 30min, and mixing well.
(3) Mixing the powder, making soft mass with 95% ethanol, sieving with 20 mesh sieve, granulating, drying at 60-70 deg.C for 0.5-2 hr, and grading with 20 mesh sieve to obtain granule.
(4) Taking 4g of magnesium stearate, sieving with a 80-mesh sieve, mixing with the granules for 5min, and mixing uniformly to obtain mixed powder.
(5) And (4) taking the total granules and filling the granules into capsules to obtain the capsule.
Comparative example 4 is example 1 provided by the present invention.
4. Influence of the product of the invention on the antioxidant capacity of human body
4.1 general conditions of the study subjects
4.1.1 escape and escape Rate of study
A total of 300 volunteer participants were selected as study subjects according to inclusion criteria and exclusion criteria, 9 individuals of the control group and the test group were separated from the study, and the separation rate of the five groups of study subjects was 15%.
4.1.2 study balance comparison
As can be seen from Table 3-2, the differences of MDA content, SOD activity, GSH-Px activity, sex and age before eating test group and the control group are not significant (p is more than 0.05).
TABLE 3-2 two sets of equilibrium comparisons
4.2 physical examination of the subjects
Before and after the test, abnormal changes are not found in blood routine, urine routine, stool routine, blood biochemical indexes, chest radiography, electrocardiogram and B-ultrasonic examination of the abdomen of the five groups of study subjects.
4.3 antioxidant index of the study
4.3.1 Effect on lipid peroxide content
TABLE 3-3 Effect of test substances on MDA content
P <0.05 in self-comparison, P <0.05 in comparison with control group, and abcP <0.05 in comparison with control group
As can be seen from tables 3-3, the difference of the MDA content in comparison between the pre-test food and the post-test food of the test food groups 3 and 4 is significant (P is less than 0.05), and the difference is lower after the test food than before the test food; compared with the MDA content difference before and after the test of the test group 1-2 and the control group, the MDA content difference is not significant (P is more than 0.05); compared with a control group, the test groups 1 to 4 before test feeding have no significant difference of MDA content (P is more than 0.05); the difference of MDA content in the test group after test feeding is significant (P is less than 0.05). Compared with the test group 1-3 and the control group, the test group 4 after the test has significant difference of MDA content (P is less than 0.05), and the test group 3 after the test has significant difference of MDA content (P is less than 0.05) compared with the test group 1-2 and the control group.
4.3.2 Effect on glutathione peroxidase Activity
Tables 3-4 Effect of test substances on GSH-Px Activity
P <0.05 in self-comparison, P <0.05 in comparison with control group, and abc P <0.05 in comparison with test group
As can be seen from tables 3-4, the GSH-Px activity difference before and after the test feeding of the test feeding group 4 has significance (P is less than 0.05), and the activity difference after the test feeding is lower than that before the test feeding; the GSH-Px activity difference of the test groups 1-3 and the control group before and after the test is not significant (P is more than 0.05); the difference of GSH-Px activity of the test groups 1-4 before the test and the control group is not significant (P is more than 0.05); after the test diet, the test diet group 4 has significant GSH-Px activity difference (P is less than 0.05) compared with the test diet groups 1-3 and the control group.
4.3.3 Effect on superoxide dismutase Activity
Tables 3-5 Effect of test substances on SOD Activity
P <0.05 in self-comparison, P <0.05 in comparison with control group, and abc P <0.05 in comparison with test group
As can be seen from tables 3-5, the SOD activity difference before and after the test eating of the test eating group 4 is significant (P is less than 0.05), and the SOD activity difference after the test eating is higher than that before the test eating; compared with the SOD activity difference before and after the test feeding of the test feeding groups 1-3 and the control group, the SOD activity difference is not significant (P is more than 0.05); compared with a control group, the test groups 1 to 4 have no significant SOD activity difference (P is more than 0.05) before test eating; compared with the test groups 1-3 and the control group, the test group 4 has significant SOD activity difference (P is less than 0.05).
5. Conclusion
Two control designs of the test subject and the control subject are adopted, 255 effective test subjects meet the requirements, and 51 test subjects and 51 control subjects are respectively contained in 4 groups of the test food group. The test group takes the tested sample according to the requirement, and the control group adopts a blank control. The life and eating habits are kept in a normal day during the test period, and no adverse reaction is caused after the test period of taking the medicine for 3 months. The MDA content, GSH-Px and SOD activity of the test group and the control group are not obviously different before the test and have comparability; compared with the test group 4 before and after the test, the MDA content is averagely reduced (0.45 +/-0.62) nmol/mL (P is less than 0.05), and the reduction percentage is 5.98%; the average activity of GSH-Px is increased (11.43 +/-16.95) U/mL (P is less than 0.05), and the increase rate is 8.20%; the SOD activity is averagely increased (5.16 +/-4.26) U/mL (P is less than 0.05), and the increase rate is 7.20%. After the test, the MDA content of the test group 4 is reduced (P is less than 0.05) compared with the test groups 1-3 and the control group; the activity of GSH-Px is increased (P is less than 0.05); the SOD activity is increased (P is less than 0.05). The results show that the compound nutrient preparation with the antioxidant function provided by the invention has the antioxidant function and has obvious antioxidant effect compared with the comparative examples 1-3.
Claims (9)
1. The compound nutrient composition with the antioxidant function is characterized by comprising the following raw materials in parts by weight: 30-70 parts of grape seed extract, 20-50 parts of tea polyphenol and 2-10 parts of selenium-enriched yeast.
2. The composite nutrient composition according to claim 1, comprising the following raw materials in parts by weight: 35-60 parts of grape seed extract, 20-40 parts of tea polyphenol and 3-9 parts of selenium-enriched yeast.
3. The composite nutrient composition according to claim 2, comprising the following raw materials in parts by weight: 38 parts of grape seed extract, 25 parts of tea polyphenol and 4 parts of selenium-enriched yeast.
4. The composite nutrient composition of any one of claims 1-3, wherein the feedstock further comprises at least one of a Rosa roxburghii extract, a Lycium barbarum extract.
5. The complex nutrient composition of any one of claims 1-3, wherein the composition is prepared as a solid formulation.
6. The complex nutrient composition of claim 5, wherein the solid formulation is a capsule, a tablet, an effervescent, or a granule.
7. The composite nutrient composition as claimed in claim 6, wherein one or more of an auxiliary filler, a disintegrant, a lubricant, an effervescent disintegrant are added in the preparation of the solid preparation.
8. The composite nutrient composition according to claim 7, wherein the filler is selected from one or more of starch, compressible starch, microcrystalline cellulose, dextrin, sucrose, lactose, mannitol, and inorganic salts, the disintegrant is selected from one or more of dry starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, and croscarmellose sodium, the lubricant is selected from one or more of magnesium stearate, aerosil, talc, polyethylene glycol 400, polyethylene glycol 6000, and hydrogenated vegetable oil, and the effervescent disintegrant is sodium bicarbonate and citric acid.
9. Use of a complex nutrient composition according to any one of claims 1-8 in the preparation of an antioxidant product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011252060.4A CN112156143B (en) | 2020-11-11 | 2020-11-11 | Compound nutrient composition with antioxidant function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011252060.4A CN112156143B (en) | 2020-11-11 | 2020-11-11 | Compound nutrient composition with antioxidant function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112156143A CN112156143A (en) | 2021-01-01 |
| CN112156143B true CN112156143B (en) | 2021-11-30 |
Family
ID=73865897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011252060.4A Active CN112156143B (en) | 2020-11-11 | 2020-11-11 | Compound nutrient composition with antioxidant function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112156143B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113615833A (en) * | 2021-07-01 | 2021-11-09 | 泓博元生命科技（深圳）有限公司 | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof |
| CN115153020A (en) * | 2022-07-29 | 2022-10-11 | 武汉橙炻科技有限公司 | Medicinal and edible food capable of efficiently removing harmful free radicals from human body and preparation method of medicinal and edible food |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103504292A (en) * | 2012-06-29 | 2014-01-15 | 刘凤琪 | Grape seed effervescent tablet |
-
2020
- 2020-11-11 CN CN202011252060.4A patent/CN112156143B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112156143A (en) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6436449B2 (en) | Use of a composition | |
| JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
| CN104739921B (en) | A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue | |
| CN107822948B (en) | Composition with after-sun repair, oxidation resistance and whitening effects and preparation method thereof | |
| JP2015529670A (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| WO2002100329A2 (en) | Methods and compositions for helping the body resist the effects of the aging process | |
| CN112156143B (en) | Compound nutrient composition with antioxidant function | |
| KR20200120465A (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
| CN101433314B (en) | Health care food with fatigue resistance and oxidation resistance functions | |
| KR101517833B1 (en) | A composotion for the treatment of dyslipidemia comprising the red ginseng complex | |
| EP1261358B1 (en) | Use of a composition comprising morinda citrifolia for the treatment of tinnitus | |
| KR102189415B1 (en) | Compositions for preventing or improving the UV-induced skin damage comprising the extract of Eisenia bicyclis as an active ingredient | |
| Barua et al. | An overview on pharmacological activities of Musa sapientum and Musa paradisiaca | |
| KR20100114349A (en) | Anti-aging composition containing red-grape-leaf extract, berrylike mixtures and selenium | |
| Uka et al. | Phytochemicals, acute toxicity and in-vitro antioxidant activity of ethanol extract of Sphenocentrum jollyanum leaves | |
| CN105101817A (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| Abuh et al. | Hypoglycaemic activity of Anthocleista vogelii (Planch) aqueous extract in rodents | |
| RU2125815C1 (en) | Biologically active food additive "adaptovit" | |
| CN112043816A (en) | Antioxidant and anti-aging composition, and preparation and application thereof | |
| CN112843155B (en) | Composition suitable for puerpera and used for removing freckles and relieving lumbago | |
| CN109157548A (en) | It is a kind of with antifatigue and Yang strengthening function composition and preparation method | |
| CN103006830B (en) | Traditional Chinese medicine composition for treating type-2 diabetes | |
| JP2003073289A (en) | Active oxygen scavenger | |
| CN101401877A (en) | Composition capable of restraining and removing free radical | |
| CN103006921A (en) | Composition having health care effects on cardiovascular and cerebrovascular anoxia and on toxicity of excess oxidation to human body, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |